| Title |
RRx-001, A novel dinitroazetidine radiosensitizer
|
|---|---|
| Published in |
Investigational New Drugs, February 2016
|
| DOI | 10.1007/s10637-016-0326-y |
| Pubmed ID | |
| Authors |
Bryan Oronsky, Jan Scicinski, Shoucheng Ning, Donna Peehl, Arnold Oronsky, Pedro Cabrales, Mark Bednarski, Susan Knox |
| Abstract |
The 'holy grail' in radiation oncology is to improve the outcome of radiation therapy (RT) with a radiosensitizer-a systemic chemical/biochemical agent that additively or synergistically sensitizes tumor cells to radiation in the absence of significant toxicity. Similar to the oxygen effect, in which DNA bases modified by reactive oxygen species prevent repair of the cellular radiation damage, these compounds in general magnify free radical formation, leading to the permanent "fixation" of the resultant chemical change in the DNA structure. The purpose of this review is to present the origin story of the radiosensitizer, RRx-001, which emerged from the aerospace industry. The activity of RRx-001 as a chemosensitizer in multiple tumor types and disease states including malaria, hemorrhagic shock and sickle cell anemia, are the subject of future reviews. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 21% |
| Other | 4 | 12% |
| Student > Master | 3 | 9% |
| Student > Postgraduate | 3 | 9% |
| Researcher | 3 | 9% |
| Other | 7 | 21% |
| Unknown | 7 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 12% |
| Biochemistry, Genetics and Molecular Biology | 4 | 12% |
| Engineering | 3 | 9% |
| Nursing and Health Professions | 3 | 9% |
| Other | 8 | 24% |
| Unknown | 7 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 March 2024.
All research outputs
#4,775,189
of 23,342,092 outputs
Outputs from Investigational New Drugs
#166
of 1,190 outputs
Outputs of similar age
#83,692
of 399,587 outputs
Outputs of similar age from Investigational New Drugs
#2
of 14 outputs
Altmetric has tracked 23,342,092 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,190 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 399,587 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.